An observational study in Myocardial Infarction, sponsored by Weill Cornell Medical College in Qatar. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Weill Cornell Medical College in Qatar · Observational
The goal of this observational study is to learn whether a non-invasive electromagnetic wave scanner (EDE CARDIO BIO-MAP) can help diagnose myocardial infarction (heart attack) in adults (18 years and older) who come to the emergency department with chest pain and suspected myocardial infarction. The main questions it aims to answer are:
Participants will:
Myocardial infarction is a leading cause of death and disability worldwide. Current diagnosis relies on clinical assessment, electrocardiogram, and blood measurement of cardiac biomarkers such as troponin. Faster, non-invasive diagnostic tools could be especially valuable in the emergency setting, where timely intervention is critical.
The Exponential Deep Examination Cardio Bio-Map is a non-invasive device, classified as Class 1 under the European Conformity marking system, that analyzes passive electromagnetic signals (0.1 to 300 gigahertz) using artificial intelligence to measure cardiac biomarkers without a blood draw. Results are available within 50 milliseconds. The device does not collect or store patient data. It produces an immediate printed report, and all data processing occurs locally within Qatar. During the COVID-19 pandemic, the same technology detected the SARS-CoV-2 virus with a specificity of 95.62% and a sensitivity of 93.71% compared with polymerase chain reaction testing and antibody testing. This study will evaluate whether the device can screen for myocardial infarction through measurement of cardiac biomarkers, both in biological samples (in vitro, using a portable laboratory device) and directly in patients (in vivo, using the scanner).
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
This study's planned enrollment of 200 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Weill Cornell Medical College in Qatar is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited at Hamad Medical Corporation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sensitivity and specificity of the EDE CARDIO BIO-MAP scanner(in vivo) for detecting myocardial infarction
Sensitivity (true positives / \[true positives + false negatives\]) and specificity (true negatives / \[true negatives + false positives\]) of the scanner in emergency room patients with suspected myocardial infarction, compared with standard hospital laboratory results (cardiac troponin, creatine kinase-myocardial band, myoglobin, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide) and the final clinical diagnosis in the medical record.
Time frame: Baseline
Sensitivity and specificity of the portable lab's immediate blood measurements (in vitro)
Sensitivity and specificity of the portable lab's immediate blood measurements for myocardial infarction, compared with conventional hospital laboratory measurements, using a confusion matrix.
Time frame: Baseline
Accuracy of the EDE scanner
Accuracy = (true positives + true negatives) / all results;
Time frame: Baseline
Misclassification rate of the EDE scanner
Misclassification rate = (false positives + false negatives) / all results;
Time frame: Baseline
Precision of the EDE scanner
precision = true positives / (true positives + false positives)
Time frame: Baseline
Accuracy of the portable lab
Accuracy = (true positives + true negatives) / all results;
Time frame: Baseline
Misclassification rate of the portable lab
Misclassification rate = (false positives + false negatives) / all results;
Time frame: Baseline
Precision of the portable lab
precision = true positives / (true positives + false positives)
Time frame: Baseline
Correlation Between EDE Scanner and Portable Laboratory Values for Cardiac Biomarkers
Pearson or Spearman correlation coefficient between scanner and portable lab values for cardiac biomarkers : Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB.
Time frame: Baseline
Predictive power of each cardiac biomarker for myocardial infarction
Logistic regression, area under the receiver operating characteristic curve, and optimal diagnostic cutoffs for each cardiac biomarker: Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB.
Time frame: Baseline
Change in cardiac biomarker levels between initial assessment and 4-6 hour follow-up
Change in cardiac biomarker levels( Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB) between the initial assessment and the follow-up, in participants who have a second clinical blood draw.
Time frame: Baseline and 4-6 hours after initial assessment
Diagnostic performance of the scanner by sex
Subgroup analysis of scanner sensitivity and specificity by sex
Time frame: Baseline
Diagnostic performance of the scanner by age group
Subgroup analysis of scanner sensitivity and specificity by age group
Time frame: Baseline
Diagnostic performance of the scanner by symptom profile
Subgroup analysis of scanner sensitivity and specificity by symptom profile.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: Undecided — ongoing discussion with the sponsor
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Cornell Medical College in Qatar